Keyphrases
Cell Death
100%
Breast Cancer Cells
100%
PARP Inhibitor (PARPi)
100%
Sigma-2 Ligand
100%
Sigma-2 Receptor Ligands
80%
Breast Cancer Cell Lines
40%
Sigma-2 Receptor
40%
Induced Cell Death
40%
Poly(ADP-ribose) Polymerase
40%
Olaparib
40%
Cancer Therapy
20%
M Phase
20%
Therapeutic Target
20%
Cell Proliferation
20%
Tumor Cells
20%
Positron Emission Tomography
20%
Proliferating Cells
20%
Solid Tumors
20%
Induced Apoptosis
20%
Cytotoxicity
20%
DNA Damage Response
20%
Mouse Breast Cancer
20%
Quiescent Cells
20%
MDA-MB-231
20%
Cell Viability Assay
20%
EMT6
20%
MDA-MB-231 Cells
20%
Inhibitor-2
20%
Colony Formation Assay
20%
Triple Negative Cell Lines
20%
Medicine and Dentistry
Cancer Cell
100%
Cell Death
100%
Breast Cancer
100%
Sigma 2 Opiate Receptor
100%
PARP Inhibitor
100%
Cell Proliferation
33%
Breast Cancer Cell Line
33%
Poly ADP Ribose Polymerase
33%
Olaparib
33%
Cancer Therapy
16%
Positron Emission Tomography
16%
Tumor Cell
16%
Cell Cycle
16%
Programmed Cell Death
16%
Solid Malignant Neoplasm
16%
Cell Cycle M Phase
16%
Cytotoxicity
16%
DNA Damage Response
16%
Cell Viability Assay
16%
MDA-MB-231 Cell Line
16%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Sigma 2 Opiate Receptor
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
33%
Olaparib
33%
Neoplasm
16%
Malignant Neoplasm
16%
Solid Malignant Neoplasm
16%
Cell Viability
16%
Viability Assay
16%
Cytotoxicity
16%
Immunology and Microbiology
Cell Death
100%
Cancer Cell
100%
Cell Proliferation
40%
Breast Cancer Cell Line
40%
Tumor Cell
20%
Positron Emission Tomography
20%
Cell Cycle
20%
Cell Cycle M Phase
20%
Cytotoxicity
20%
DNA Damage Response
20%
Cell Viability
20%
MDA-MB-231 Cell Line
20%
Programmed Cell Death
20%